US Treasury Department drafts rules for pharma licensing deals with China

Pfizer: Pfizer is a leading global pharmaceutical company focused on developing and commercializing medicines across therapeutic areas including oncology. Company executives have met with Trump administration officials to advocate against broad curbs on licensing deals involving Chinese drug developers. The firm has highlighted the value of accessing promising medicines regardless of their development location. Albert Bourla: Albert Bourla is the CEO of Pfizer, a major US pharmaceutical company. He has directly engaged with senior administration officials including Treasury Secretary Scott Bessent and Secretary of State Marco Rubio to discuss China-related investment policies. Bourla has publicly stated that licensing medicines from Chinese companies does not pose national security concerns. Scott Bessent: Scott Bessent is the US Treasury Secretary in the Trump administration. He has participated in meetings with pharmaceutical industry leaders regarding proposed rules on outbound investment and licensing deals with China. Bessent's department is leading the drafting of the framework expected to balance national security with industry access to Chinese drug development. Debbie Dingell: Debbie Dingell is a Democratic US Representative from Michigan. She has joined efforts with Republican lawmakers to advocate for greater scrutiny of US pharmaceutical investments and licensing deals involving Chinese companies. Dingell supports measures to address competitive risks in biotechnology innovation. John Moolenaar: John Moolenaar is a Republican US Representative from Michigan who chairs the House Select Committee on the Chinese Communist Party. He has pushed for stricter Treasury oversight of biotechnology transactions with Chinese entities using existing national security authorities. Moolenaar co-sponsored legislation aimed at tightening regulation of licensing agreements and joint ventures to protect US biotech leadership. Jake Auchincloss: Jake Auchincloss is a Democratic US Representative whose Massachusetts district includes numerous life sciences companies. He has argued against applying semiconductor-style restrictions to biotechnology, noting China's independent investments in the sector. Auchincloss has cautioned that attempts to curb US engagement would likely fail to slow Chinese progress. Innovent Biologics: Innovent Biologics is a Chinese biotechnology company specializing in the development of innovative therapies, particularly in oncology. It has been referenced in discussions of US pharma partnerships as an example of ongoing licensing activity between American and Chinese firms. The company maintains operations in Shanghai amid evolving US regulatory considerations. US Treasury Department: The US Treasury Department is the federal agency responsible for economic policy, financial regulation, and national security-related investment rules. It is currently drafting a framework for US pharmaceutical companies' investments and licensing deals with Chinese firms. The rules under consideration aim to limit restrictions to sensitive areas like pathogens and weaponizable biotech while allowing most other deals. Policy Framework: The US Treasury is developing rules that would focus restrictions on pharmaceutical deals involving pathogens or weaponizable technologies rather than imposing broad limits on licensing arrangements with Chinese firms. Industry Position: Major US drugmakers have met with Trump administration officials to argue that broad curbs on Chinese licensing deals would limit access to a growing source of new medicines. Congressional Debate: Lawmakers are divided, with some pushing for tighter controls on biotech investments in China to address strategic dependence concerns while others warn such measures cannot halt China's independent advancements in the field.